Loading…

Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa

Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aerugi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2009-12, Vol.34 (6), p.589-591
Main Authors: Shigemi, Akari, Matsumoto, Kazuaki, Yaji, Keiko, Shimodozono, Yoshihiro, Takeda, Yasuo, Miyanohara, Hiroaki, Kawamura, Hideki, Orita, Michiyo, Tokuda, Koichi, Nishi, Junichiro, Yamada, Katsushi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193
cites cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193
container_end_page 591
container_issue 6
container_start_page 589
container_title International journal of antimicrobial agents
container_volume 34
creator Shigemi, Akari
Matsumoto, Kazuaki
Yaji, Keiko
Shimodozono, Yoshihiro
Takeda, Yasuo
Miyanohara, Hiroaki
Kawamura, Hideki
Orita, Michiyo
Tokuda, Koichi
Nishi, Junichiro
Yamada, Katsushi
description Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.
doi_str_mv 10.1016/j.ijantimicag.2009.07.017
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734121107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0924857909003720</els_id><sourcerecordid>734121107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</originalsourceid><addsrcrecordid>eNqNkkuv1CAUgBuj8Y5X_4LBhbpqPdBSysbETHwlN9FEXRMKp1dqCyO06vx76Z2JGhfGFQG-88j5TlE8olBRoO2zsXKj9oubndHXFQOQFYgKqLhV7GgnWCkkrW8XO5CsKTsu5EVxL6URgPK64XeLCypF07Ga7oof-xAjTnpxwZMel--InswYwwE9zkR7S2yI7nRbExKLPrnlePOzfEbivHH5zSAJAzE69vqGLSMml5bcJXmfcLVhDl4nojGu186HpO8XdwY9JXxwPi-LT69efty_Ka_evX67f3FVmkaypbQt5xxsh9AaYP3QgxQ1h8EOWth2wAEYr1tGGZfcaonA9TYi2dUWB01lfVk8PeU9xPB1xbSo2SWD06Q9hjUpUTeUUQoik0_-SWaKy65lGZQn0MSQUsRBHaKbdTwqCmqrrkb1hyC1CVIgVBaUYx-ei6z9jPZ35NlIBh6fAZ2Mnoao84DTL46x7FDwLnP7E4d5eN8cRpWM2zxYF9Esygb3X-08_yuLmZzP2PQFj5jGsEaf7SiqElOgPmwbtS0USIBaMKh_AmGHy7w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21159862</pqid></control><display><type>article</type><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><source>ScienceDirect Journals</source><creator>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</creator><creatorcontrib>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</creatorcontrib><description>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2009.07.017</identifier><identifier>PMID: 19748231</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobial use density ; beta-Lactam Resistance ; Biological and medical sciences ; Carbapenems ; Carbapenems - pharmacology ; Carbapenems - therapeutic use ; Cross-resistance ; Drug Utilization - statistics &amp; numerical data ; Humans ; Infectious Disease ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - isolation &amp; purification ; Pseudomonas Infections - microbiology ; Statistics as Topic ; Susceptibility ; Thienamycins - therapeutic use</subject><ispartof>International journal of antimicrobial agents, 2009-12, Vol.34 (6), p.589-591</ispartof><rights>Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2009 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</citedby><cites>FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22153758$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19748231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shigemi, Akari</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Yaji, Keiko</creatorcontrib><creatorcontrib>Shimodozono, Yoshihiro</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><creatorcontrib>Miyanohara, Hiroaki</creatorcontrib><creatorcontrib>Kawamura, Hideki</creatorcontrib><creatorcontrib>Orita, Michiyo</creatorcontrib><creatorcontrib>Tokuda, Koichi</creatorcontrib><creatorcontrib>Nishi, Junichiro</creatorcontrib><creatorcontrib>Yamada, Katsushi</creatorcontrib><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobial use density</subject><subject>beta-Lactam Resistance</subject><subject>Biological and medical sciences</subject><subject>Carbapenems</subject><subject>Carbapenems - pharmacology</subject><subject>Carbapenems - therapeutic use</subject><subject>Cross-resistance</subject><subject>Drug Utilization - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - isolation &amp; purification</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Statistics as Topic</subject><subject>Susceptibility</subject><subject>Thienamycins - therapeutic use</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkkuv1CAUgBuj8Y5X_4LBhbpqPdBSysbETHwlN9FEXRMKp1dqCyO06vx76Z2JGhfGFQG-88j5TlE8olBRoO2zsXKj9oubndHXFQOQFYgKqLhV7GgnWCkkrW8XO5CsKTsu5EVxL6URgPK64XeLCypF07Ga7oof-xAjTnpxwZMel--InswYwwE9zkR7S2yI7nRbExKLPrnlePOzfEbivHH5zSAJAzE69vqGLSMml5bcJXmfcLVhDl4nojGu186HpO8XdwY9JXxwPi-LT69efty_Ka_evX67f3FVmkaypbQt5xxsh9AaYP3QgxQ1h8EOWth2wAEYr1tGGZfcaonA9TYi2dUWB01lfVk8PeU9xPB1xbSo2SWD06Q9hjUpUTeUUQoik0_-SWaKy65lGZQn0MSQUsRBHaKbdTwqCmqrrkb1hyC1CVIgVBaUYx-ei6z9jPZ35NlIBh6fAZ2Mnoao84DTL46x7FDwLnP7E4d5eN8cRpWM2zxYF9Esygb3X-08_yuLmZzP2PQFj5jGsEaf7SiqElOgPmwbtS0USIBaMKh_AmGHy7w</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Shigemi, Akari</creator><creator>Matsumoto, Kazuaki</creator><creator>Yaji, Keiko</creator><creator>Shimodozono, Yoshihiro</creator><creator>Takeda, Yasuo</creator><creator>Miyanohara, Hiroaki</creator><creator>Kawamura, Hideki</creator><creator>Orita, Michiyo</creator><creator>Tokuda, Koichi</creator><creator>Nishi, Junichiro</creator><creator>Yamada, Katsushi</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20091201</creationdate><title>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</title><author>Shigemi, Akari ; Matsumoto, Kazuaki ; Yaji, Keiko ; Shimodozono, Yoshihiro ; Takeda, Yasuo ; Miyanohara, Hiroaki ; Kawamura, Hideki ; Orita, Michiyo ; Tokuda, Koichi ; Nishi, Junichiro ; Yamada, Katsushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobial use density</topic><topic>beta-Lactam Resistance</topic><topic>Biological and medical sciences</topic><topic>Carbapenems</topic><topic>Carbapenems - pharmacology</topic><topic>Carbapenems - therapeutic use</topic><topic>Cross-resistance</topic><topic>Drug Utilization - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - isolation &amp; purification</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Statistics as Topic</topic><topic>Susceptibility</topic><topic>Thienamycins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shigemi, Akari</creatorcontrib><creatorcontrib>Matsumoto, Kazuaki</creatorcontrib><creatorcontrib>Yaji, Keiko</creatorcontrib><creatorcontrib>Shimodozono, Yoshihiro</creatorcontrib><creatorcontrib>Takeda, Yasuo</creatorcontrib><creatorcontrib>Miyanohara, Hiroaki</creatorcontrib><creatorcontrib>Kawamura, Hideki</creatorcontrib><creatorcontrib>Orita, Michiyo</creatorcontrib><creatorcontrib>Tokuda, Koichi</creatorcontrib><creatorcontrib>Nishi, Junichiro</creatorcontrib><creatorcontrib>Yamada, Katsushi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shigemi, Akari</au><au>Matsumoto, Kazuaki</au><au>Yaji, Keiko</au><au>Shimodozono, Yoshihiro</au><au>Takeda, Yasuo</au><au>Miyanohara, Hiroaki</au><au>Kawamura, Hideki</au><au>Orita, Michiyo</au><au>Tokuda, Koichi</au><au>Nishi, Junichiro</au><au>Yamada, Katsushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>34</volume><issue>6</issue><spage>589</spage><epage>591</epage><pages>589-591</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Abstract Optimal use of carbapenems is an important issue in the prevention of resistance in Pseudomonas aeruginosa . In this study, we investigated the correlation between antimicrobial use density (AUD) of carbapenems and imipenem/cilastatin (IPM/CS) or meropenem (MEPM) susceptibility of P. aeruginosa strains. The AUD of five carbapenems [IPM/CS, panipenem/betamipron, biapenem, MEPM and doripenem (DRPM)] was examined every 6 months between 2006 and 2008. The AUD was calculated using the defined daily doses methodology developed by the World Health Organisation. A minimum inhibitory concentration of IPM/CS or MEPM of ≤4 mg/L was considered to be sensitive. There was a significant negative correlation between MEPM susceptibility and the total AUD of MEPM and DRPM [ r = −0.823, 95% confidence interval (CI) −0.035 to −0.980; P = 0.044]. Furthermore, there was a significant correlation between MEPM susceptibility and IPM/CS susceptibility ( r = 0.839, 95% CI 0.084 to 0.981; P = 0.037). Cross-resistance was therefore investigated and only 5.6% of MEPM-insensitive strains were susceptible to IPM/CS, although 43.3% of IPM/CS-insensitive strains were susceptible to MEPM. These results suggest that curtailing the use of MEPM and DRPM may curb the emergence not only of MEPM-resistant strains but also IPM/CS-resistant strains.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19748231</pmid><doi>10.1016/j.ijantimicag.2009.07.017</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0924-8579
ispartof International journal of antimicrobial agents, 2009-12, Vol.34 (6), p.589-591
issn 0924-8579
1872-7913
language eng
recordid cdi_proquest_miscellaneous_734121107
source ScienceDirect Journals
subjects Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antimicrobial use density
beta-Lactam Resistance
Biological and medical sciences
Carbapenems
Carbapenems - pharmacology
Carbapenems - therapeutic use
Cross-resistance
Drug Utilization - statistics & numerical data
Humans
Infectious Disease
Medical sciences
Microbial Sensitivity Tests
Pharmacology. Drug treatments
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - isolation & purification
Pseudomonas Infections - microbiology
Statistics as Topic
Susceptibility
Thienamycins - therapeutic use
title Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A50%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20meropenem%20and%20doripenem%20use%20density%20and%20the%20incidence%20of%20carbapenem-resistant%20Pseudomonas%20aeruginosa&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Shigemi,%20Akari&rft.date=2009-12-01&rft.volume=34&rft.issue=6&rft.spage=589&rft.epage=591&rft.pages=589-591&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2009.07.017&rft_dat=%3Cproquest_cross%3E734121107%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c492t-d65550d8e06c02bfb097350fdfa7d6fef02536212595da9e05a1016983defa193%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21159862&rft_id=info:pmid/19748231&rfr_iscdi=true